Healthcare Edge – Page 3 – ExecEdge

Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug

Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug

By Karen Roman Ascentage Pharma Group International (Nasdaq: AAPG) said China’s National Medical Products Administration (NMPA) approved the use of lisaftoclax for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. The authorization makes lisaftoclax the first inhibitor of...

Deborah Geraghty Named President & CEO of Radiant Biotherapeutics

Deborah Geraghty Named President & CEO of Radiant Biotherapeutics

By Karen Roman Toronto-based biotech company Radiant Biotherapeutics announced the designation of Deborah Geraghty, Ph.D., as President and Chief Executive Officer. The company also appointed Stefan Larson, Ph.D., as Chair of the Board of Directors, and Ingmar Bruns, M.D., Ph.D.,...

Study Shows Results for SkylineDx’s Test for Early-Stage Melanoma

Study Shows Results for SkylineDx’s Test for Early-Stage Melanoma

By Karen Roman Oncology-focused biotech company SkylineDx said an independent study shows that Merlin CP-GEP, the company’s test for treatment decisions in early-stage melanoma, correctly categorizes patients with skin melanoma for sentinel lymph node biopsy (SLNB). Merlin acts as a...

Study Confirms SKY92 Test Improves Multiple Myeloma Risk Assessment

Study Confirms SKY92 Test Improves Multiple Myeloma Risk Assessment

By Daniella Parra A new study published in the British Journal of Haematology confirms that the SKY92 gene expression profiling test significantly enhances risk stratification in multiple myeloma patients, outperforming traditional clinical markers, SkylineDx said. Risk stratification by SKY92 showed...

Input your search keywords and press Enter.